Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd. develops and commercializes minimally invasive microwave ablation (MWA) medical devices, with a focus on thyroid-related diseases and other soft tissue conditions. News about BDMD commonly covers sales of MWA needles and microwave therapeutic apparatuses, distributor and direct-customer activity, clinical education for physicians, and the company's geographic expansion beyond Mainland China.
Updates also include regulatory clearances in international markets, U.S. clinical-conference engagement, and product-development work tied to software, AI-assisted planning, and robotic surgical systems. Financial releases discuss revenue mix, gross margin, R&D spending, and the effects of market policy and pricing dynamics on the company's China business.
Baird Medical (BDMD) reported preliminary unaudited results showing revenue of approximately $9.9 million for the six months ended June 30, 2026, up 24.6% from $8.0 million a year earlier.
Growth was driven mainly by markets outside mainland China, with about two thirds of revenue generated internationally and the United States and Hong Kong as key contributors. Gross profit rose to $8.6 million from $6.5 million, lifting gross margin to 87.0% from 82.1%, helped by geographic and product mix shifts. Total operating expenses dropped to $7.8 million from $17.0 million, as sharply lower research and development and general and administrative costs more than offset higher selling and marketing spend tied to the U.S. commercial ramp.
Net income was $13,499, compared with a net loss of $11.4 million in the prior-year period. EBITDA improved to about $1.6 million from negative $9.7 million, and adjusted EBITDA reached approximately $4.0 million versus negative $3.3 million, reflecting higher gross profit and reduced operating expenses.
Baird Medical (NASDAQ: BDMD) reported that its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (DRAP), strengthening the company’s regulatory base and supporting ongoing commercial activities in Pakistan.
The registrations build on earlier approvals and initial availability at the Armed Forces Institute of Radiology & Imaging in January 2026. Baird Medical highlighted this as part of its broader international expansion, noting first microwave ablation procedures earlier in 2026 by physicians in Vietnam and Argentina.
Baird Medical (NASDAQ: BDMD) and Tianjin Yuanshan Medical Technology, operating as Alpmed, signed a strategic cooperation agreement to form a long-term partnership for global development and commercialization of next-generation irreversible electroporation (IRE) ablation technologies.
The collaboration combines Alpmed's IRE innovation with Baird Medical's clinical, regulatory, and global commercialization capabilities. The partners plan to submit a 510(k) application to the U.S. FDA by the end of 2026 for their first co-developed IRE device, intended for ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. According to Baird Medical, it will lead global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product as part of its strategy to expand beyond microwave ablation and build a diversified minimally invasive treatment portfolio.
Baird Medical (NASDAQ: BDMD) announced successful first microwave ablation (MWA) procedures using its technology in Vietnam and Argentina.
The thyroid case in Vietnam and liver ablation in Argentina mark entry into two new markets, supporting Baird Medical's global expansion of minimally invasive treatment options.
Baird Medical (NASDAQ: BDMD) is relocating its global headquarters to New York City, centralizing corporate leadership in the U.S. as part of its global growth strategy in minimally invasive microwave ablation technology.
The move follows the December 2025 appointment of Mark Saxton as CEO of the U.S. subsidiary to lead domestic operations and commercial expansion. The New York headquarters is intended to improve access to U.S. healthcare investors and support a growing national sales force and physician/KOL network, while global operations continue across key healthcare markets.
Baird Medical (NASDAQ: BDMD) reported full year 2025 revenue of $22.5 million, down 39.2% from $37.0 million in 2024, driven mainly by policy-related slowdown in Mainland China. Gross margin was 83.8% and loss from operations was $25.6 million. Total operating expenses rose to $44.5 million, including $17.5 million of one-time share-based compensation. The company named Mark Saxton CEO of Baird U.S. and established a North American production hub with MPS Medical to support U.S. commercial expansion and product advancement.
Baird Medical (NASDAQ: BDMD) executed two expert-led clinical training workshops in Indonesia on March 16, 2026. The sessions at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital delivered hands-on instruction in minimally invasive Microwave Ablation (MWA) platforms.
Attending physicians practiced MWA techniques for a variety of soft tissue conditions to support regional adoption and smoother clinical integration of Baird Medical's technologies across Southeast Asia.
Baird Medical (NASDAQ: BDMD) announced regulatory clearance of its minimally invasive Microwave Ablation systems in Argentina on March 12, 2026. This approval expands the company’s international certifications beyond the United States FDA to include Indonesia, Malaysia, and Vietnam.
According to the company, Baird Medical is pursuing formal registration in Egypt, Sri Lanka, the Philippines, Pakistan, and other markets to broaden global patient access to its MWA technology.
Baird Medical (NASDAQ: BDMD) reported a strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, advancing its U.S. expansion for minimally invasive microwave ablation (MWA) technology. The company highlighted clinical applications at a thermal ablation workshop and engaged Key Opinion Leaders and emerging physicians.
Leadership said the engagements aim to accelerate adoption of precision, non-surgical interventions to expand patient access and elevate standards of care across the United States.
Baird Medical (NASDAQ: BDMD) announced completion of development for its cross-platform, AI-driven surgical software and has begun regulatory registration in the United States, European Union, and China on March 4, 2026. The system automates anatomical mapping, dynamic treatment planning, and procedural simulations using a proprietary AI model.
The software integrates diverse diagnostic imaging and is engineered to connect with Baird Medical's upcoming automated surgical robotic system, aiming to create a closed-loop surgical ecosystem spanning pre-, intra- and post-operative workflows and to accelerate the company's commercial roadmap.